Alnylam

Alnylam Announces Encouraging Exploratory Cardiac Endpoint Data For Patisiran in hATTR Amyloidosis
Fri, 09/14/18 - 09:35 am
Alnylam
hATTR amyloidosis
Patisiran
FDA Approves Eight Novel Drugs in August
BioSpace
Sat, 09/1/18 - 04:17 pm
Kyowa Hakko Kirin
Poteligeo
Alnylam
Onpattro
Amicus Therapeutics
Galafold
TherapeuticMD
Annovera
Biocodex
Diacomit
Dompe Group
Oxervate
Shire
Takhzyro
Merck
Pifeltro
6 Things Alnylam Investors Need to Know About Pfizer's Next Blockbuster Drug
Motley Fool
Tue, 08/28/18 - 10:18 am
Alnylam
Onpattro
Pfizer
ATTR amyloidosis
tafamidis
Vyndaqel
2 Blockbuster New Drug Launches Making Investors Nervous Right Now
Motley Fool
Sun, 08/26/18 - 12:01 pm
drug launches
Alnylam
GW Pharma
Onpattro
Epidiolex
3 Things Alnylam's Management Wants Investors to Know About the Launch of Onpattro
Motley Fool
Mon, 08/20/18 - 10:05 am
Alnylam
Onpattro
hATTR amyloidosis
drug pricing
labeling
2 Reasons Alnylam Stock Fell on a Landmark Drug Approval
Motley Fool
Fri, 08/17/18 - 09:25 pm
Alnylam
FDA
Onpattro
hATTR amyloidosis
3 Hurdles Ahead of Alnylam and Its Revolutionary New Drug
Motley Fool
Wed, 08/15/18 - 10:13 pm
Alnylam
Onpattro
RNAi
After Alnylam’s solo maiden launch, here comes the tricky bit
EP Vantage
Tue, 08/14/18 - 12:06 am
Alnylam
drug launches
FDA
RNAi
Patisiran
Onpattro
Alnylam Prices First Gene Silencing Drug At $450,000 Per Patient, But Offers Money-Back Guarantee
Forbes
Sun, 08/12/18 - 01:19 pm
Alnylam
FDA
drug pricing
hATTR amyloidosis
Onpattro
In first, FDA approves RNA interference drug from Alnylam
Biopharma Dive
Fri, 08/10/18 - 02:25 pm
Alnylam
RNAi
FDA
Patisiran
Onpattro
hATTR amyloidosis
With patisiran launch in its sights, Alnylam plots a major hiring spree
Fierce Pharma
Tue, 08/7/18 - 12:02 pm
Alnylam
Patisiran
RNAi
hirings
Alnylam Pharmaceuticals Is "Launch Ready"
Motley Fool
Mon, 08/6/18 - 11:51 pm
Alnylam
FDA
Onpattro
TTRsc02
lumasiran
The Week Ahead In Biotech: Conferences, PDUFA Dates And IPOs
Yahoo/Benzinga
Sun, 08/5/18 - 07:25 pm
biotech
IPOs
Pain Therapeutics
Remoxy
Vertex Pharmaceuticals
lumacaftor/ivacaftor
Alnylam
Patisiran
Regeneron
Eylea
Insmed
Paratek
Vaccinex
The UK's MHRA Grants Early Access to Anlylam's Patisiran
CP Wire
Fri, 08/3/18 - 09:23 am
Alnylam
Patisiran
hATTR amyloidosis
UK
The UK's MHRA Grants Early Access to Anlylam's Patisiran
Fri, 08/3/18 - 09:01 am
Alnylam
Patisiran
hATTR amyloidosis
Alnylam Receives Positive CHMP Opinion for Hereditary Amyloidosis Treatment
CP Wire
Fri, 07/27/18 - 10:22 am
Alnylam
Patisiran
EMA
hATTR amyloidosis
Alnylam Receives Positive CHMP Opinion for Hereditary Amyloidosis Treatment
Fri, 07/27/18 - 10:01 am
Alnylam
Patisiran
hATTR amyloidosis
Alnylam Presents Ph III results of Patisiran in Hereditary ATTR (hATTR) Amyloidosis
CP Wire
Mon, 07/23/18 - 09:42 am
Alnylam
Patisiran
hereditary ATTR amyloidosis
Alnylam Presents Ph III results of Patisiran in Hereditary ATTR (hATTR) Amyloidosis
Mon, 07/23/18 - 09:40 am
Alnylam
hereditary ATTR amyloidosis
Patisiran
Poised to launch its first marketing effort, Alnylam makes a big leap into CNS diseases and Alzheimer’s
Endpoints
Tue, 05/8/18 - 08:22 pm
Alnylam
RNAi
Alzheimer's disease

Pages